Full-Time

Executive Director

Corporate Affairs, Executive Thought Leadership

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$284.1k - $322.1k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Thousand Oaks, CA, USA

In Person

Category
Content Strategy
Creative Writing
Content & Writing
Copywriting
Required Skills
Journalism
Requirements
  • Doctorate degree & 6 years of experience in executive communications, speechwriting, journalism, strategic communications
  • Master’s degree & 10 years of experience in executive communications, speechwriting, journalism, strategic communications
  • Bachelor’s degree & 12 years of experience executive communications, speechwriting, journalism, strategic communications
  • 6 years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs or directing the allocation of resources
Responsibilities
  • Develop and execute end-to-end thought leadership strategy
  • Write and edit speeches, talking points, panel scripts, video remarks, and presentation decks for the CEO and other senior executives
  • Collaborate with subject matter experts across scientific, business, and corporate affairs functions to translate complex content into accessible, compelling narratives
  • Support executive presence across internal town halls, industry conferences, media engagements, and investor events
  • Align messaging with corporate strategy, tone, and voice, ensuring consistency across platforms and speakers
  • Maintain an editorial calendar for key leadership speaking and visibility opportunities and deliverables
  • Stay current on industry issues, company priorities, and competitor narratives to inform messaging strategy
  • Provide rapid-response writing support as needed for priority communications moments
Desired Qualifications
  • 15+ years of experience in executive communications, speechwriting, journalism, or strategic communications
  • Experience in the biopharma, biotech, or life sciences industry is preferred
  • Ability to write for senior executives and adapt tone and style to reflect individual voice
  • Scientific and financial fluency — able to quickly grasp and communicate complex concepts
  • Sharp editorial judgment, with strong storytelling, structure, and message discipline
  • Highly collaborative, discreet, and comfortable working in a fast-paced, high-stakes environment
  • Bachelor’s degree required; advanced degree (e.g., MS, MPH, PhD) a plus

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.